FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval | FDA
The FDA converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval.| U.S. Food and Drug Administration
The FDA converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval.| U.S. Food and Drug Administration
Learn more about Biogen's strategic realignment from Aduhelm's controversy to Leqembi's promise in Alzheimer's treatment.| Labiotech.eu
